Divi's Laboratories Limited vs Jenburkt Pharmaceuticals Ltd

A side-by-side comparison of Divi's Laboratories Limited (DIVISLAB) and Jenburkt Pharmaceuticals Ltd (JENBURKTPHARMACEUTICALSLTD) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Divi's Laboratories Limited leads DIVISLAB vs JENBURKTPHARMACEUTICALSLTD on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability22
  • Growth20
  • Size & financial health40
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

JENBURKTPHARMACEUTICALSLTD takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

94.52
P/E ratio
14.10
14.90
P/B ratio
2.36
0.32%
Dividend yield
1.71%
₹96.75
EPS
₹72.64

Profitability

Even

How efficiently each company turns capital and sales into profit. Higher is better.

15.32%
Return on equity
20.20%
20.35%
Return on capital
27.00%
32.59%
EBITDA margin
27.00%
24.32%
Net margin
21.05%

Growth

DIVISLAB takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
9.32%
12.09%
Profit CAGR (3Y)
11.55%

Size & financial health

DIVISLAB takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹2.45L Cr
Market cap
₹462 Cr
₹10,560 Cr
Revenue
₹152 Cr
₹2,568 Cr
Net profit
₹32 Cr
0.00
Debt / equity
0.01
Divi's Laboratories Limited
  • + ["Company has been maintaining a healthy dividend payout of 31.0%", "Company is almost debt free."]
  • − ["Stock is trading at 14.60 times its book value", "The company has delivered a poor sales growth of 8.7% over past five years."]
Jenburkt Pharmaceuticals Ltd
  • + ["Company has reduced debt.", "Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • − ["The company has delivered a poor sales growth of 9.08% over past five years."]
Divi's Laboratories Limited full analysis Jenburkt Pharmaceuticals Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.